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Abstract It has been reported that methylated analog of
resveratrol, 3,4,5,40-trans-tetramethoxystilbene (DMU-
212), demonstrates strong antiproliferative, and proapop-
totic activity. The aim of this study was to evaluate the
effect of DMU-212 on the activation of nuclear factor-jB
(NF-jB), activator protein-1 (AP-1), and signal transducer
and activator of transcription 3 (STAT3) transcription
factors, using a two-stage model of rat hepatocarcinogen-
esis (HCC) in Wistar rats. Initiation was performed by a
single intraperitoneal injection of N-nitrosodiethylamine
(NDEA) (200 mg/kg) followed by promotion with pheno-
barbital (PB) (0.05 %) in drinking water. DMU-212 was
administered by gavage in a dose of 20 or 50 mg/kg b.w.
two times a week for 16 weeks. There was a significant
increase in the activation of all investigated hepatic tran-
scription factors in the NDEA/PB-induced rats. The acti-
vation of NF-jB induced by NDEA/PB treatment was
suppressed by DMU-212 as evidenced by a reduction of
p65 and p50 subunits translocation, DNA binding capacity,
increased retention of IjB, and the reduced IKK activity.
Moreover, DMU-212 reduced the level of iNOS protein
induced by NDEA/PB. Treatment with DMU-212 alone
increased the constitutive AP-1 subunits c-Jun and c-Fos
levels and c-Jun binding to TRE consensus site. The
combined treatment diminished c-Fos level and DNA
binding. At a dose of 50 mg/kg, DMU-212 decreased also
the STAT3 activation induced by NDEA/PB. These data
indicate that DMU-212 may suppress pro-inflammatory
transcription factors, particularly NF-jB, and in conse-
quence iNOS expression in rat model of HCC which makes
DMU-212 a good candidate for the development of HCC
chemopreventive agent.
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Introduction
Resveratrol (3, 40, 5-trihydroxystilbene), a naturally
occurring phytoalexin found in grapes, red wines, berries
and peanuts, has been reported to show a variety of bene-
ficial properties including antioxidative and anticarcino-
genic ones [1, 2]. Resveratrol has been demonstrated to
affect a multitude of signal transduction pathways associ-
ated with tumorigenesis [3], thus the pleotropic activity,
rather than just a single effect, seems to play an important
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role in the potential anticancer properties of stilbenoids.
These promising data have encouraged the search for
resveratrol’s derivatives showing enhanced biological
activity as well as improved pharmacokinetic parameters.
Compared to resveratrol, its analogs with ortho-methoxy
substituents have been found to be more potent in some
in vitro and in vivo studies. Thus such derivatives,
including trans-3,4,5,40-tetramethoxystilbene (DMU-212),
may serve as a useful starting point for the design of
improved chemopreventive or cancer therapeutic agents
[4]. Our earlier studies have shown that this derivative
exerts stronger antiproliferative and proapoptotic activity
than the parent compound in ovarian cancer cells culture
in vitro [5]. Similar observations have been also reported
by other researchers in different cell systems [4, 6].
Proapototic activity is often linked to enhanced activa-
tion of nuclear factor kappa B (NF-jB) and activator
protein-1 (AP-1). These transcription factors as well as
signal transducers and activators of transcription 3
(STAT3) are constitutively active in many kinds of cancers
including liver cancer, and play critical roles in tumor
development and progression through modulation of their
target genes involved in angiogenesis, metastasis, and cell
survival [7, 8]. Moreover, STAT3 is considered as the
marker of metastasis [9].
Liver cancer, predominantly hepatocellular carcinoma
(HCC), is a complex and fatal malignancy, driven pri-
marily by oxidative stress and inflammation. Because of
the lack of effective diagnostic tools for early detection and
limited treatment options available to patients with
advanced stages of HCC, there is a critical need for dis-
covery and development of novel preventive and thera-
peutic strategies to combat the current morbidity and
mortality associated with HCC [10].
Resveratrol has been shown to prevent N-nitrosodi-
ethylamine (NDEA) initiated hepatocarcinogenesis in rats
through suppression of inflammation and oxidative stress
[11, 12]. Resveratrol-mediated chemoprevention of rat
liver carcinogenesis has been suggested to be related to
alteration of proinflammatory cytokines [12]. A number
of transcription factors have been connected to the
inflammation and oxidative stress. Among them, the
most important are NF-jB and AP-1. Activation of NF-
jB leads to transcription of numerous genes including
those encoding for expression of inflammatory cytokines,
and cyclooxygenase-2 (COX-2) [13]. Another proin-
flammatory protein/enzyme transcriptionally regulated by
NF-jB and/or AP-1 is inducible nitric oxide synthase,
iNOS [14].
In view of the above, the aim of our current study was to
investigate whether DMU-212, a methylated resveratrol
analog, may exert chemopreventive, anti-apoptotic, and
antinflammatory effects through modulation of transcription
factors NF-jB, AP-1, and STAT3 induced by NDEA/PB
regimen in rat liver.
Materials and methods
Materials
3,4,5,40-trans-tetramethoxystilbene (DMU-212) was syn-
thesized by partial methylation of trans-resveratrol as
described elsewhere. Its structure and purity was confirmed
by means of gas chromatography–mass spectrometry and
nuclear magnetic resonance spectroscopy [15].
Rabbit polyclonal p50, p65, c-Jun, c-Fos, iNOS, COX-2,
JNK, IjBa, IKKa/b, and pSTAT3 antibodies, anti-rabbit
IgG-alkaline phosphatase (AP) conjugated antibody, and
anti-rabbit IgG-horseradish peroxidase (HRP) conjugated
antibody were supplied by Santa Cruz Biotechnology
(Santa Cruz, CA, USA). SDS-PAGE Gels (5–10 %) and
Western blotting detection system were purchased from
Bio-Rad Laboratories (Hercules, CA, USA). AP-1 and NF-
jB activation tests were supplied from Active Motif
(Carlsbad, CA, USA). Substrate peptides for IKK activity
assay were purchased from GL Biochem (Shanghai,
China). NDEA and phenobarbital (PB) were provided by
Sigma-Aldrich Poland, 2-hydroxypropyl-b-cyclodextrin by
Bonio Inc., Canada.
Animals and treatment
Two stage model of hepatocarcinogenesis, initiation by
NDEA and promotion by phenobarbital, was applied. Male
Wistar rats, 240 ± 10 % g, bred at the Department of
Toxicology, Poznan University of Medical Sciences were
used. The rats were housed in animal facility, at 22 ± 2 C
with a 12 h light/dark cycle, controlled humidity and cir-
culation of air, and fed certified laboratory feed (Labofeed
H, ISO 22000). Animals were divided randomly into 5
groups, 8 animals each and subjected to the following
treatment. Rats in group II were administered DMU-212 by
gavage at a dose 50 mg/kg b.w. two days a week for
16 weeks. To improve bioavailability, the compound was
suspended in the 40 % solution of 2-hydroxypropyl-b-
cyclodextrin [16]. Groups III, IV, and V were given
intraperitoneally a single dose of NDEA, 200 mg/kg b.w.,
followed by promotion with phenobarbital at a concentra-
tion of 0.05 % in drinking water. Promotion was started
2 weeks after NDEA injection. Rats in groups IV and V
were administered DMU-212 by gavage at doses 20 and
50 mg/kg b.w., respectively, two days a week for 16 con-
secutive weeks. Rats in group I (controls) were given
vehicle by gavage (40 % solution of 2-hydroxypropyl-b-
cyclodextrin) two days a week for 16 weeks.
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After 16 weeks following NDEA injection, the animals
were anesthetized by ketamine and xylazine, the blood was
withdrawn from the heart, livers were excised, rinsed with
ice-cold 1.5 % KCl, and stored in -70 C until isolation of
extracts or subcellular fractions.
The experiment was performed according to the Local Ani-
mal Ethics Committee guidelines for animal experimentation.
Preparation of liver extracts
The pre-cut livers were placed in Total Protein Isolation
Buffer (TPIB; 50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 %
NP-40, 0.1 % SDS, 1 mM EDTA, 1 mM PMSF, 1 mM
Na3VO4, 1 mM NaF), containing protease inhibitors (leu-
peptin and aprotinin, 1 lg/ml each), homogenized in ice-
chilled glass homogenizer with Teflon pestle, lysed for 40 min
on ice with vortex mixing every 10 min, and centrifuged at
15,000 g for 30 min at 4 C. Supernatants were collected,
assayed for protein concentration using the Lowry method,
aliqoted and stored at -70 C until used for analysis.
Preparation of nuclear and cytosolic extracts
Nuclear and cytosolic extracts were prepared using
Nuclear/Cytosol Fractionation Kit (BioVision Research)
according to the manufacturer’s instructions. Briefly, liver
homogenate was centrifuged at 500 g for 5 min at 4 C.
Pellets were resuspended in an ice-cold cytosol extraction
buffer containing dithiothreitol (DTT) and protease inhib-
itors. After incubation in an ice bath for 10 min, 11 ll of
Cytosol Extraction Buffer B were added, the samples were
mixed and then centrifuged at 16,000 g for 5 min 4 C to
collect the cytosolic fractions. The supernatants (cytosolic
fractions) were transferred into clean tubes. The pellets
were resuspended in an ice-cold nuclear extraction buffer
containing DTT and protease inhibitors and incubated on
ice for 40 min with vortex mixing for 15 s every 10 min.
The lysed suspension of nuclei was then centrifuged at
16,000 g at 4 C for 10 min, and the supernatants were
collected as nuclear fractions. The collected cytosolic and
nuclear fractions were assayed for protein concentration
using the Lowry method, aliquoted and stored at -70 C
until used for Western blot or ELISA analysis.
Western blot analysis
For the analysis of protein level, the total cell extracts or
subcellular fractions were boiled in loading buffer (2.7 M
Tris–HCl, 20 % SDS, 80 % glycerol, 250 mM DTT, 0.01 %
bromophenol blue). Thirty micrograms of the sample protein
were resolved on polyacrylamide gels (Biorad). The
resolved proteins were transferred to a PVDF membrane
(Millipore). The blot containing the transferred protein was
blocked in a blocking buffer (10 % fat-free milk in DPBS-T,
containing 10 mM Tris–HCl, pH 7.6, 150 mM NaCl, and
0.1 % Tween-20). The blots were then incubated for 2 h with
primary antibodies dissolved in DPBS-T, washed three times
and subsequently incubated for 1 h with secondary anti-
bodies conjugated with alkaline phosphatase. After washing
three times with DPBS-T and two times with TBS (20 mM
Tris–HCl, 500 mM NaCl; pH 7.4), the blots were placed in
0.1 M Tris buffer (pH 9.5), and proteins were detected by
means of Alkaline Phosphatase Conjugate Substrate Kit
(BioRad Laboratories). Beta-actin was used as an internal
control. The amount of immunoreactive product in each line
was determined by densitometric scanning using a Biorad
Quantity One software. The values were calculated as rela-
tive absorbance units (RQ) per mg of protein.
NF-jB, AP-1, and STAT3: DNA binding assays
NF-jB, AP-1, and STAT3 activation was assessed by an
enzymatic immunoassay according to Renard et al. [17]
using the commercial kits (TransAM assays; Active Motif,
Carlsbad CA, USA) and following the manufacturer’s
instructions. Activated NF-jB was measured in terms of
the amount of p65, and AP-1 in terms of c-Jun/c-Fos
subunits contained in DNA-binding complex.
The proper consensus site double strand oligonucleo-
tides (50-GGGACTTTCC-30 for NF-jB, 50-TGAGTCA-30
for AP-1 and 50-TTCCCGGAA-30 for STAT3) were
immobilized on ELISA microplates as bait. The nuclear
fractions were incubated with the oligonucleotides for one
hour, the unbound proteins were washed–out, and the
DNA-bound subunits were detected with the specific pri-
mary antibody and secondary antibody conjugated with
horseradish peroxidase. The results were expressed as
absorbance (OD450 nm per mg of protein).
IKKa/b activity assay
IKKa/b activity was assessed in cytosolic fractions. IKKa/b
contained in cytosolic lysates was immunoprecipitated with
anti-IKKa/b rabbit polyclonal antibody (Santa Cruz Bio-
technology, USA), and the immunocomplex thus obtained
was incubated for 30 min at 30 C with the substrate peptides
for IKK (Biotin-LDDRHDSGLDSMK), immobilized on a
streptavidin-coated microplates (Reacti-BindTM Streptavi-
din Plate, Pierce, Rockford, IL, USA). The kinase reaction
mixture contained 50 mM HEPES, pH 7.5, 20 mM MgCl2,
0.1 mM Na3VO4, 200 lM ATP, 10 mM b-glycerolphos-
phate, and 2 mM DTT. After 30 min incubation at 30 C, the
phosphorylated peptides were detected according to the
standard ELISA procedure with the use of anti-p-Ser poly-
clonal antibody (AbD Serotec, Oxford, UK) as the primary
antibody, and anti-rabbit HRP-conjugated antibody as the
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secondary antibody. The enzyme activity was calculated on
the basis of a standard curve prepared with the phosphory-
lated substrate peptide (Biotin-LDDRHDpSGLDSMK) and
expressed as pmol of p-IjBa per min per mg of protein.
Statistical analysis
The statistical analysis was performed by one-way ANOVA.
The statistical significance between the experimental groups
and their respective controls was assessed by Tukey’s post
hoc test, with P \ 0.05 being considered significant.
Results
NF-jB activation in rat liver
Figure 1 presents the translocation of p50 and p65 subunits
of NF-jB (a, b) and binding of p65 to the consensus
sequence oligonucleotide (c) in various experimental rat
groups in comparison with untreated control. Treatment
with DMU-212 alone increased translocation of both sub-
units and the content of p65 in DNA-binding complex
extracted from the hepatocytes nuclei (by *150 and 50 %,
respectively). This effect was lower than that observed as a
result of NDEA/PB treatment protocol.
Combining this protocol with DMU-12 treatment
reduced the translocation of p50 subunit, while p65 content
in nuclei was also slightly reduced, but the difference was
not statistically significant. Treatment with a higher dose
(50 mg/kg) led to a significant decrease in p65 DNA
binding in comparison with NDEA/PB treated group of rats
(d). Figure 2 presents the data illustrating the effect of
DMU-212 on the retention of IjBa and IKKa/b protein
level in cytosol (a, b) and its activity (c). The IKKa/b is
responsible for IjBa phosphorylation and subsequent
polyubiquitination. DMU-212 alone slightly decreased
the cytosolic level of IjBa and increased the activity of
Fig. 1 The effect of DMU-212 on NF-jB activation in rat liver
translocation of p50 and p65 from cytosol to nucleus was assessed
using Western blot analysis (a). Densitometric analysis was performed
for quantitative evaluation (b, c). The blots shown are representative
from two independent assays Lane 1, 2 control group; 3, 4 DMU-212
50 mg/kg b.w.; 5, 6 NDEA (200 mg/kg); 7, 8 NDEA ? DMU-212
(20 mg/kg); 9, 10 NDEA ? DMU-212 (50 mg/kg) activated NF-jB
was assessed in terms of the amount of NF-jB p65 subunit contained in
DNA-binding complex extracted from the nuclei isolated from liver
and expressed as absorbance (OD450nm per mg protein) (d). Bars
represent mean ± SEM from 4 (b, c) or 5 (d) animals, determined by
densitometric analysis (b, c) or ELISA assay (d). * Significantly
different from control group (P \ 0.05); # significantly different from
NDEA/PB-treated group (P \ 0.05)
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IKKa/b to similar extent. These changes, however, were
not statistically significant. A similar trend, but more pro-
nounced (by *30–50 %, respectively) was observed in the
group of animals treated with NDEA/PB. The combined
treatment with DMU-212 in the dose of 50 mg/kg resulted
in an increased level of IjBa protein and reduced activity
of IKKa/b in comparison with those in the NDEA/PB-
treated group.
AP-1 activation in rat liver
AP-1 activation was evaluated in terms of the c-Jun and
c-Fos subunits protein levels (Fig. 3a, b), and their amounts
in the DNA binding complexes extracted from the hepato-
cytes nuclei (Fig. 3c). The treatment with DMU-212 alone
increased both c-Jun and c-Fos levels in comparison with
those in the control group of animals. Moreover, the treat-
ment with DMU-212 increased c-Jun binding to TRE con-
sensus site. The level of binding was significantly higher not
only in comparison with the control group of animals but also
with that treated with NDEA/PB. The combined treatment
resulted in a decrease in both AP-1 subunits protein level and
their amount in the DNA-binding complexes extracted from
the hepatocytes nuclei, however, a statistically significant
difference in comparison with NDEA/PB group of rats was
found only for c-Fos.
The effect of DMU-212 on COX-2 and iNOS protein
levels
COX-2 and iNOS genes are under transcriptional control of
NF-jB and/or AP-1, and thus, we determined the protein
level of these enzymes in the liver of rats from various
treatment groups. The application of NDEA/PB treatment
protocol resulted in an increase in COX-2 and iNOS pro-
tein level in liver cells lysates by *40 and 80 %, respec-
tively (Fig. 4). The treatment with DMU-212 alone had no
effect on these enzymes protein level, while the combined
treatment with the dose of 50 mg/kg decreased iNOS level
as compared to that in NDEA/PB-treated rats.
STAT3 activation in rat liver
Figure 5 presents the data showing the content of total and
phosphorylated transcription factor STAT3 in cell lysates
(a, b) and its binding to the consensus sequence oligonu-
cleotide in various experimental rat groups (c). The NDEA/
PB treatment regimen enhanced the STAT3 activation by
Fig. 2 The effect of DMU-212 on IjBa retention and IKKa/b level
and activity in rat liver IjBa retention and IKKa/b protein level in
cytosol were assessed using Western blot analysis (a). The blots
shown are representative from two independent assays. Lane 1, 2
control group; 3, 4 DMU-212 (50 mg/kg); 5, 6 NDEA (200 mg/kg);
7, 8 NDEA ? DMU-212 (20 mg/kg); 9, 10 NDEA ? DMU-212
(50 mg/kg). Densitometric analysis was performed for quantitative
evaluation (b). IKKa/b activity was assayed as described in the text
and is expressed as pmoles of p-IjB per minute per mg of protein (c).
Bars represent mean ± SEM from 4 (b) or 6 (c) animals,
* Significantly different from control group (P \ 0.05); # Signifi-
cantly different from NDEA/PB-treated group (P \ 0.05)
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increasing the level of its total phosphorylated form
(Fig. 5b) and protein content in DNA binding complexes
extracted from the nuclei of rat hepatocytes (Fig. 5c). The
combined treatment with DMU-212 in both doses reduced
the STAT3 activation, but the difference between both
treatment groups was statistically significant only for the
higher dose (50 mg/kg).
Discussion
Resveratrol is a simple molecule that has taken the spot-
light since the first scientific paper described a possible
cancer preventive effects on cancer in mice. Several pre-
clinical and some human intervention studies performed
later have indicated that resveratrol exerts cancer chemo-
preventive and therapeutic responses.
However, an important issue with the future application
of resveratrol for disease management is its low bioavail-
ability due to its rapid metabolism in mammals [18], hence
a strategy targeted to discover and define novel analogs of
resveratrol has been assumed. These analogs should have
the same structural backbone of resveratrol, with chemical
modifications resulting in superior efficacy [19]. One of
such analogs is DMU-212 which showed higher antipro-
liferative and proapoptotic activity as well as improved
bioavailability in mouse liver and plasma compared to
those of resveratrol [20].
The studies of Bishayee’s group have shown that res-
veratrol is able to inhibit NDEA-initiated and PB-promoted
hepatic tumorigenesis in rats [21]. Moreover, the anti-
inflammatory activity related to inhibition of iNOS induc-
tion was suggested as a possible mechanism of its anti-
promotional effects [11].
The present study was thus designed to address the
question whether DMU-212 affects NF-jB, AP-1, and
STAT3-activated inflammatory pathways, and associated
inflammatory proteins, particularly iNOS and COX-2,
using a similar experimental model. We found that
although DMU-212 increased the constitutive activation of
NF-jB when administered in a dose of 50 mg/kg, it
inhibited the NF-jB activation induced by NDEA/PB
treatment. The above observations together with the
increased retention of IjBa and reduced activity of IKKa/
b, one of the major kinases involved in NF-jB activation
pathway [22], suggest that DMU-212 affects NDEA/PB-
induced NF-jB activation through inhibition of IKKs
activity.
Fig. 3 The effect of DMU-212 on AP-1 activation in rat liver protein
extracts from rat liver were assayed for c-Jun or c-Fos using Western
blot analysis (a). The Western blots shown are representative from
two independent assays. Lane 1, 2 control group; 3, 4 DMU-212
(50 mg/kg); 5, 6 NDEA (200 mg/kg); 7, 8 NDEA ? DMU-212
(20 mg/kg); 9, 10 NDEA ? DMU-212 (50 mg/kg). Densitometric
analysis was performed for quantitative evaluation (b). Activated
AP-1 was assessed in terms of the amount of c-Jun or c-Fos subunits
contained in DNA-binding complex extracted from the nuclei isolated
from liver, and expressed as absorbance (OD450nm per mg protein) (c).
Bars represent mean ± SEM from 4 (a, b) or 6 (c) animals,
determined by means of densitometric analysis (b) or ELISA assay
(c). * Significantly different from control group (P \ 0.05);
# significantly different from NDEA/PB-treated group (P \ 0.05)
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More importantly, DMU-212 applied at the same dose
reduced the expression of NDEA/PB-induced iNOS, which
is responsible for the production of NO, one of the major
contributors to chronic inflammatory reactions. While the
role of inflammation in general is considered as an
important factor in HCC development, the evidence indi-
cating that iNOS may play particularly important role in
this process is also emerging. In this regard, iNOS over-
expression was noted in rodent as well as in human HCC
[23, 24]. Moreover, inhibition of iNOS by a selective
inhibitor, aminoguanidine, led to suppression of HCC
growth [24]. Thus, the results of our study indicate that
similarly as for resveratrol, iNOS might be one of DMU-
212 targets in prevention of HCC. The observed decrease
in the NF-kB activation indicates that the reduced iNOS
expression might be a result of its ability to modulate NF-
kB signaling.
The above mechanism is further supported by our
observation that DMU-212 did not affect the NDEA/PB-
induced AP-1 activation, which might also be responsible
for iNOS expression. Furthermore, iNOS overexpression
during hepatocarcinogenesis was shown to be a conse-
quence of NF-jB activation [24]. In contrast to iNOS,
DMU-212 treatment had no effect on COX-2 protein level.
This finding does not exclude, however, the possibility of
direct DMU-212 interaction with COX-2 protein to affect
the enzyme activity in this way. Such a mechanism of
COX-2 modulation was suggested for resveratrol [25],
although some authors, including us, have observed
reduced COX-2 protein levels as a result of treatment with
resveratrol [26, 27]. AP-1, in contrast to NF-jB, is mini-
mally activated under physiological conditions, but various
stimuli can dramatically increase the extent of its activation
[28]. Homodimers of c-Jun/c-Jun and c-Jun/c-Fos hetero-
dimers of AP-1 preferentially bind to the AP-1 consensus
sequence TRE (TGAC/GTCA). The activity of AP-1 is
regulated at the level of transcription of c-jun and c-fos
genes by protein–protein interaction and also through post-
translational modifications of c-Jun and c-Fos proteins
[29, 30].
In our study, DMU-212 significantly increased the
content of AP-1 subunits, c-Fos and c-Jun protein in rat
liver extracts. Moreover, this stilbenoid enhanced the
content of c-Jun in DNA-binding complex extracted from
the nuclei of rat liver cells, indicating its increased binding
to TRE sequence. This is an important observation since
c-Jun prolonged accumulation may lead to cell cycle arrest
or induction of apoptosis [31] and explain anti-proliferative
and pro-apoptotic activity of DMU-212 found in earlier
studies [5, 6].
On the other hand, this analog of resveratrol reduced
c-Fos protein level, as well its binding to TRE consensus,
increased by NDEA/PB treatment regimen. It was shown
recently that derepression of c-Fos caused by microRNA-
139 down-regulation contributed to the metastasis of
human HCC [32]. Thus, it may be speculated that sup-
pression of c-Fos by DMU-212 may act in the same way.
Our study showed also that DMU-212 reduced the
NDEA/PB-induced activation of STAT3. Activation of
STAT proteins usually occurs through phosphorylation on
a specific tyrosine residue (Tyr-705 in STAT3) at the
COOH terminus, but serine phosphorylation of STATs has
also been demonstrated. A Pro-X-Ser-Pro sequence that is
a recognition site of ERKs (extracellular signal-regulated
kinase) has been found at the COOH terminus of STAT3.
Moreover, it has been shown that phosphorylation on ser-
ine in DNA-binding domain of STAT3 is catalyzed by
c-Jun N-terminal protein kinase (JNK) resulting in inhibi-
tion of its DNA binding and transcriptional activities [33].
Hence, it is possible that DMU-212, similarly as many
other compounds, may activate JNK and thus phosphory-
late STAT3 and act as a negative regulator of its activity.
Such a mechanism could also explain an increased binding
of constitutive c-Jun to TRE consensus as a result of
treatment with DMU-212. Activated JNK phosphorylates
Ser 63 and Ser 73 of c-Jun and forms a complex with the
Fig. 4 The effect of DMU-212 on COX-2 and iNOS protein level in
rat liver. The levels of COX-2 and iNOS proteins in total protein
lysates of rat liver were determined using Western blotting. The blots
shown are representative from two independent experiments (a). Lane
1, 2 control group; 3, 4 DMU-212 (50 mg/kg); 5, 6 NDEA (200 mg/
kg); 7, 8 NDEA ? DMU-212 (20 mg/kg); 9, 10 NDEA ? DMU-212
(50 mg/kg). Densitometric analysis was performed for quantitative
evaluation (b). Bars represent mean ± SEM from 4 animals,
determined by densitometric analysis. * Significantly different from
control group, P \ 0.05; # significantly different from NDEA/PB-
treated group, P \ 0.05
Mol Cell Biochem (2014) 391:27–35 33
123
N-terminus of c-Jun, thereby protecting c-Jun from ubiq-
uitination and subsequent degradation [34, 35].
Collectively, the results of our present study indicate
that the resveratrol analog, DMU-212, may modulate the
signaling pathways involved in HCC development induced
by NDEA/PB initiation-promotion regimen. Although
some of these activities have been demonstrated also for
resveratrol, the higher bioavailability makes DMU-212 a
better candidate for HCC chemopreventive agent.
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